Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Mansour S Al-Moundhri, A Al-Shukaili, M Al-Nabhani, B Al-Bahrani, IA Burney, A Rizivi, SS Ganguly

Mansour S Al-Moundhri, M Al-Nabhani, IA Burney, A Rizivi, Medical Oncology Unit, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman
A Al-Shukaili, Department of Microbiology and Immunology (SQU), Muscat 123, Oman
B Al-Bahrani, National Cancer Institute, Royal Hospital, Muscat 123, Oman
SS Ganguly, Department of Epidemiology and Medical Statistics (SQU), Muscat 123, Oman

Author contributions: Al-Moundhri MS designed the research project and wrote the manuscript; Al-Moundhri MS, Al-Bahrani B, Burney IA, Rizivi A provided patient samples; Al-Shukaili A, Al-Nabhani M performed the research assay; Ganguly SS, Al-Moundhri MS performed data analysis and interpretation; Al-Bahrani B, Burney IA reviewed the manuscript.

Supported by a grant from Sultan Qaboos University Research Fund

Correspondence to: Dr. Mansour S Al-Moundhri, Associate Professor and Consultant Oncologist, Department of Medicine, College of Medicine, Sultan Qaboos University, PO Box 35, Muscat 123, Oman. mansours@squ.edu.om
Telephone: +968-99437301 Fax: +968-24141198
Received: March 26, 2008 Revised: May 19, 2008
Accepted: May 26, 2008
Published online: June 28, 2008

Abstract

AIM: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas.

METHODS: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinico-pathological features and survival rates.

RESULTS: The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P < 0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9, P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival.

CONCLUSION: Serum VEGF levels vary significantly in the same cohort of patients with variable clinico-pathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay.

© 2008 The WJG Press. All rights reserved.

Key words: Gastric cancer; Serum; Vascular endothelial growth factor; Oman

Peer reviewer: Dr. Toru Hiyama, Department of Health Service Center, Hiroshima University, 1-7-1 Kagamiyama, Hiagshihiroshima 739-8521, Japan

Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney IA, Rizivi A, Ganguly SS. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008; 14(24): 3879-3883 Available from: URL: http://www.wjgnet.com/1007-9327/14/3879.asp DOI: http://dx.doi.org/10.3748/wjg.14.3879

INTRODUCTION

Gastric cancer is the second most common cancer worldwide and remains a global health burden. The prognosis of patients with gastric cancer has been shown to be influenced by established surgical-pathological features, such as pathological stage, location of the tumor, and histological type and grade of the tumor. In comparison, the intense search for predictive molecular biomarkers has not yet translated into clinical use. There is growing recognition of the central role that the vascular endothelial growth factor (VEGF) family plays in angiogenesis in which the formation of new blood vessels is necessary for the growth and spread of tumors. The VEGF family consists of seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E,
VEGF-F, and placental growth factor (PIGF)-which share eight cysteine residues in a VEGF homology domain[9,10]. The members act through specific tyrosine kinase receptors, VEGFR-1, -2 and -3. VEGF-A acts through VEGFR-1 and -2 receptors, VEGF-C and -D act through VEGFR-2 and -3[11].

Studies have shown an association between intratumoral microvessel density and tumor aggressiveness in gastric cancer[12,13]. Among angiogenic stimulators, VEGF-A plays an essential role in both vasculogenesis and angiogenesis[14]. Serum concentrations of VEGF-A have been examined in patients with gastric cancer and a relationship between the serum concentration of VEGF and metastasis and/or poor outcome has been demonstrated[15,16]. However, the significance of other VEGF family members (VEGF-B, -C, and -D) in tumor angiogenesis and metastasis are not fully demonstrated[17]. Recently, the prognostic importance of serum concentrations of other VEGF family members (VEGF-C and -D and their receptors) in gastric cancer has been reported[18,19]. Overall, these studies were limited to one or two VEGF family members and their receptors and did not examine the full profile of expression of these proteins in the same patient[4,15,18].

In the current study, we evaluated the serum levels of VEGF-A, -C, and -D, and their receptors, VEGFR-1 and -2 in both healthy controls and gastric cancer patients. We then correlated these serum levels with clinico-pathological features and patient survival rates.

**MATERIALS AND METHODS**

**Study subjects**

The study population consisted of a series of unrelated patients diagnosed with gastric cancer in three main hospitals in the Sultanate of Oman (Sultan Qaboos University Hospital, Royal Hospital, and Sohar Hospital). The control group was composed of subjects of the same ethnic and geographical origin as the patients. The Medical Research and Ethics Committee of the College of Medicine of Sultan Qaboos University approved the study design. The study subjects gave an informed consent prior to participation in the study.

**Serum VEGF family level assay**

Peripheral venous blood samples were obtained prior to any treatment and allowed to clot at room temperature and centrifuged at 2000 g for 10 min. Sera were separated, aliquoted, and stored at -70°C until assay. Serum VEGF concentrations were determined using a commercially available enzyme-linked immunoassay (ELISA) designed to measure VEGF-A (VEGF 165), VEGF-C, VEGF-D, VEGFR-1, and VEGFR-2 levels (Quantikine, R&D Systems Europe, Abingdon, UK). Assays employed the quantitative sandwich enzyme immunoassay and were performed according to the manufacturer's procedure.

**Statistical analysis**

The significance of differences in the levels of various VEGF molecules between patients and controls was studied using the unpaired t test and further confirmed with Mann-Whitney U test. The significance of the correlations between the expression of various VEGF proteins and clinico-pathological features was evaluated by the Spearman's correlation test.

Overall survival rates were determined from the time of biopsy-proven diagnosis until either the time of death or last known follow-up examination. The dates of death were obtained from either medical records or phone contact. The Kaplan-Meier method was used to estimate overall survival time, and the statistical significance was determined by log-rank test. Backward conditional Cox proportional hazards regression model was utilized for multivariate analyses where age (≤ 40 years, > 40 years), gender, proximal or distal location, histological classification (intestinal vs non-intestinal), T stage (1 + 2 vs 3 + 4), presence or absence of lymph node metastasis, overall all stage (1 + II vs III + IV), tumor differentiation (well vs moderate + poor), all the VEGF factors were included. P values less than 0.05 were considered statistically significant. Analysis of data was performed using SPSS 10.0 software.

**RESULTS**

A total of 76 gastric cancer patients and 76 unrelated controls were included. The age range for the participants included in the study was 21-82 years; the mean and standard deviation of ages for the patients and controls were 55.7 ± 11.3 and 38.5 ± 10.2 years, respectively. The proportion of males (n = 41) and females (n = 35) were equal in both groups. Fifty four patients received either chemotherapy alone or chemoradiotherapy.

| Table 1  Serum concentrations (pg/mL) of VEGF-A, -C, and -D, and VEGFR-1 and -2 in patients with gastric adenocarcinoma and control subjects (n = 76) |
|-----------------|-----------------|-----------------|-----------------|
|   Patients     | Control         | P               |
|----------------|-----------------|-----------------|
| VEGF-A         | 385.7 ± 408.4   | 444.9 ± 529.9   | 0.02            |
| VEGF-C         | 4693 ± 1927.7   | 346.9 ± 630.6   | 0.004           |
| VEGF-D         | 483.0 ± 259.3   | 671.1 ± 501.8   | 0.0001          |
| VEGFR-1        | 428.9 (205.7-1355.2) | 605.9 (205.7-3859.7) | 0.45            |
| VEGFR-2        | 783.7 ± 360.8   | 645.3 ± 297.9   |                 |
| 1026.4 (279.4-1767.6) | 475.4 (224.1-1333.6) |                 |
| 9266.5 ± 2111.1 | 9420.3 ± 1840.7 |                 |
| 9382.3 (4726.1-15427.3) | 9386.2 (3272.9-15433.3) |                 |

1Refers to mean ± SD; median (range).

The serum values of VEGF-A, -C, and -D levels and VEGFR-1 and -2 in patients with gastric cancer and controls. The serum VEGF-A and VEGFR-1 levels were significantly higher in patients with gastric cancer than controls.
in healthy donors ($P = 0.02$ and $P = 0.0001$, respectively). Interestingly, the serum levels of VEGF-D were higher in controls than in patients with gastric cancer. There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls.

**The association between serum values of VEGF-A, -C, -D, and VEGFR-1 and -2 and clinico-pathological features**

Table 2 shows the association between serum values of VEGF-A, -C, -D and VEGFR-1 and -2 and clinico-pathological features. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall tumor stage, and tumor differentiation. VEGF-2 levels were associated with poor tumor differentiation.

**Correlation between circulating VEGF levels and patient survival**

Elevated serum VEGF levels were defined as greater than the 95th percentile in the healthy control group as previously described. There was no significant predictive value for any of the VEGF's or their receptors (data not shown) except for VEGFR-1 as shown in Figure 1. The median survival time for patients with high and low levels of VEGFR-1 was 5 mo (95% CI 2.6-7.4) and 13 mo (95% CI 1.4-24.6), respectively. The 5-year survival rates were 20% and 36%, respectively ($P = 0.02$). Multivariate regression analysis showed that only advanced stage III and IV (Hazard ratio 6.7; 95% CI, 2.2-20.0; $P = 0.001$) to be a significant independent factor.

**DISCUSSION**

Studies on the role of the VEGF family in gastric cancer have focused on individual VEGF members and their respective receptors. The evaluation of the simultaneous expression of VEGF family members and their receptors may provide more accurate prognostic information. Therefore, we have investigated the serum levels of VEGF-A, -C, -D, and VEGFR-1 and -2 and studied their predictive and prognostic significance in the same group of patients.

In the present study, the VEGF-A and VEGFR-1 levels are higher in patients with gastric cancer than in healthy controls, which is consistent with results from other studies. However, we found that serum VEGF-D levels were higher in the control group than in patients with gastric cancer. George et al. studied VEGF-A, -C, and -D mRNA tissue expression in colorectal cancer progression, demonstrating that VEGF-D mRNA remained at persistently low levels in carcinomas compared with adenomas, and that
both VEGFR-2 and VEGFR-3 mRNA expression levels remained constant. This result suggested that VEGF-D acts as a competitive agonist with VEGF-A and VEGF-C; a decrease in VEGF-D levels may allow increased access of VEGF-A and VEGF-C, which are more potent angiogenic cytokines than VEGF-D, to the two VEGF receptors[22]. It has been previously shown that tissue expression of certain VEGF family members correlates with their serum levels[18]. Therefore, the advanced tumor stage presentation that predominated in the current cohort of patients may have led to the differential expression of the VEGF family members, further emphasizing the importance of the simultaneous measurement of these factors.

The correlation of markers of angiogenesis and clinico-pathological features further highlights the complex interaction between various factors and their respective receptors[16,23]. Whereas VEGF-A and -D did not correlate with any of the clinico-pathological features studied, it is interesting to note the strong association between VEGFR-1 and advanced stage cancer, the presence of metastasis, and poor tumor differentiation. VEGF-C was a serum biomarker for advanced tumor stage and poor differentiation, whereas VEGF-R2 correlated with poor tumor differentiation. It is interesting that serum VEGF-C and -D levels did not correlate with lymph node metastasis, a result that has been shown previously[18]. This finding is most likely due to the fact that most patients included had lymph node metastasis and, therefore, such differences could not be found (Table 2).

The available data on the prognostic significance of serum VEGF levels in malignancies is controversial[24-26]. The prognostic significance of VEGF (in particular, of VEGF-A), as determined by ELISA, has been commonly studied in various tumors[24-27]. It has been shown that high serum VEGF levels correlate with poor prognosis in certain hematological malignancies[26,29]. In gastric cancer, it has been shown that serum VEGF-A levels correlated with local tumor extent, disease stage, and the presence of distant metastases, and is an independent prognostic factor for patient survival[14,15,20]. Recently, Wang et al[30] reported that serum VEGF-C levels might be a useful biomarker to determine the presence of lymph node metastasis in patients with gastric cancer as well as correlate with VEGF-C tissue expression[31]. Juttner et al[8] showed that both VEGF-D and VEGF-R3 are independent prognostic biomarkers to identify patients with poor prognosis after curative resection of gastric adenocarcinomas; when combined with an analysis of VEGF-C, patients with shorter survival times could be predicted[17]. In the current study, a significant correlation between VEGFR-1 and advanced tumor stage, presence of metastasis, and poor tumor differentiation in turn reflects poor survival outcome as shown in Figure 1. To our knowledge, this is the first study to report on the prognostic significance of serum VEGFR-1 levels in patients with gastric cancer. It has been suggested that the VEGFR-1/VEGF ratio in sera may be of greater prognostic value than VEGF levels alone[30], hence, overcoming the limitations of a single biomarker assay[27,30].

In conclusion, we have demonstrated that there are significant variations in VEGF serum concentrations when measured simultaneously that correlate with important variations in clinico-pathological features and prognostic significance. Future work will address the application of this concept on a larger cohort of patients to generate a predictive profile that examines the simultaneous expression of these proteins at the tissue level.

REFERENCES

1 Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006; 10: 345-352
2 Al-Moundhri MS, Al-Bahraini B, Burney IA, Nirmala V, Al-Madhani A, Al-Mawaly K, Al-Nabhani M, Thomas V, Ganguly SS, Grant CS. The prognostic determinants of gastric cancer treatment outcome in Omani Arab patients. Oncology 2006; 70: 90-36
3 Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H. Prevalence and
prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007; 22: 1435-1442

4 Barchielli A, Amorosi A, Balzì D, Crocetti E, Nesì G. Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987. Eur J Cancer 2001; 37: 1674-1680

5 Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly S, Grant C. The prognostic significance of p53, p27kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 2005; 91: 243-252

6 Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 2004; 51: 1544-1547

7 Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hyodo I, Saito H, Miyata T. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007; 37: 275-281

8 Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D, Harris AL. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651-663

9 Otroczek ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258-268

10 Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition--a critical review. Anticancer Agents Med Chem 2007; 7: 223-245

11 Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res 2007; 27: 3245-3250

12 Zhao HC, Qin R, Chen XX, Sheng X, Wu JF, Wang DB, Chen GH. Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol 2006; 12: 7598-7603

13 Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L. Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther 2007; 6: 269-275

14 Aoyagi K, Kouchi K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005; 8: 155-163

15 Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37-42

16 Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS, Kim HJ. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008; 8: 123

17 Jutttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmerer W, Hocker M. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-240

18 Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13: 1794-1797; discussion 1797-1798

19 Tas F, Duraynilidiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006; 16: 405-411

20 Ding S, Lin S, Dong X, Yang X, Qu H, Huang S, Liu W, Zhou L, Liu D. Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. In Vivo 2005; 19: 793-795

21 Ohma T, Konno H, Tanaka T, Baba M, Kamiya K, Syoju T, Kondoh K, Watanabe M, Terada H, Nakamura S. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett 2003; 192: 215-225

22 George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001; 3: 420-427

23 Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30: 633-637

24 Tas F, Duraynilidiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 2006; 24: 576-580

25 Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007; 27: 3481-3487

26 Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicouzono G, Rocci L, Rosaria VM, Gebbia N, Tonini G. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007; 8: 319-327

27 Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-3126

28 Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur J Haematol 2003; 70: 420-427

29 Rippe RA, Zhang WB